Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy

被引：7
|
作者：
Galli, Giulia [1 ]
Proto, Claudia [1 ]
Signorelli, Diego [1 ]
Imbimbo, Martina [1 ]
Ferrara, Roberto [1 ]
Prelaj, Arsela [1 ]
De Toma, Alessandro [1 ]
Ganzinelli, Monica [1 ]
Zilembo, Nicoletta [1 ]
de Braud, Filippo [1 ,2 ]
Garassino, Marina C. [1 ]
Lo Russo, Giuseppe [1 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Unit Thorac Oncol, Dept Med Oncol, Via G Venezian 1, I-20133 Milan, Italy
[2] Univ Milan, Dept Med Oncol & Hematol, Via Festa Perdono 7, I-20122 Milan, Italy
来源：
FUTURE ONCOLOGY | 2019年 / 15卷 / 23期
关键词：
disease response; immunotherapy; long-term benefit; non-small-cell lung cancer; survival; OPEN-LABEL; LIGAND; NIVOLUMAB; DOCETAXEL; SURVIVAL; PEMBROLIZUMAB; CHEMOTHERAPY; MULTICENTER; MONOTHERAPY; INHIBITION;
D O I：
10.2217/fon-2019-0055
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: A minority of patients gains advantage from immunotherapy (IO). Predictive variables of long-term benefit (LTB) are incompletely understood. Materials & methods: We retrospectively collected data about metastatic non-small-cell lung cancer patients treated with IO from April 2013 to July 2017. We defined LTB to IO as complete response (CR), partial response (PR) or disease stability as best response and maintaining it for >= 12 months. Results: Thirty-five of the 147 patients had LTB. More LTB patients than controls showed CR/PR as first and best response to IO. Only CR/PR as best response to IO retained association to LTB at multivariate analyses. Conclusion: Objective response appears as a central factor for LTB from IO.
引用
收藏
页码：2743 / 2757
页数：15
相关论文
共 50 条
  • [1] Characterization of patients with metastatic non-small cell lung cancer obtaining long term benefit from immunotherapy
    Galli, G.
    Proto, C.
    Signorelli, D.
    Imbimbo, M.
    Ferrara, R.
    Prelaj, A.
    De Toma, A.
    Randon, G.
    Trevisan, B.
    Ganzinelli, M.
    Zilembo, N.
    Garassino, M. C.
    Lo Russo, G.
    ANNALS OF ONCOLOGY, 2019, 30 : 56 - 56
  • [2] Long-term benefit of immunotherapy in metastatic non-small cell lung cancer: the tale of the tail
    Daylan, Ayse Ece Cali
    Halmos, Balazs
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (07) : 1636 - 1642
  • [3] Long-Term Survival of Patients with Metastatic Non-Small-Cell Lung Cancer over Five Decades
    Bar, Jair
    Urban, Damien
    Amit, Uri
    Appel, Sarit
    Onn, Amir
    Margalit, Ofer
    Beller, Tamar
    Kuznetsov, Teodor
    Lawrence, Yaacov
    JOURNAL OF ONCOLOGY, 2021, 2021
  • [4] Quantifying the benefit of non-small-cell lung cancer immunotherapy
    Ludmir, Ethan B.
    Mccaw, Zachary R.
    Grossberg, Aaron J.
    Wei, Lee-jen
    Fuller, C. David
    LANCET, 2019, 394 (10212): : 1904 - 1904
  • [5] Which non-small-cell lung cancer patients achieve long-term survival?
    Ahbeddou, N.
    Fetohi, M.
    Boutayeb, S.
    Errihani, H.
    INDIAN JOURNAL OF CANCER, 2011, 48 (04) : 514 - U1
  • [6] Long-term Outcomes and Toxicity in Patients with Metastatic Non Small Cell Lung Cancer Treated with Immunotherapy Containing Regimens
    Maddula, M.
    Brown, L. J.
    Gao, B.
    da Silva, I. Pires
    Nagrial, A.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S622 - S622
  • [7] Treatment patterns in patients with metastatic non-small-cell lung cancer in the era of immunotherapy
    Stenehjem, David
    Lubinga, Solomon
    Betts, Keith A.
    Tang, Wenxi
    Jenkins, Mads
    Yuan, Yong
    Hartman, John
    Rao, Sumati
    Lam, Jenny
    Waterhouse, David
    FUTURE ONCOLOGY, 2021, 17 (22) : 2940 - 2949
  • [8] Clinical and Genomic Characterization of Long-Term Responders Receiving Immune Checkpoint Blockade for Metastatic Non-Small-Cell Lung Cancer
    Ghanem, Paola
    Murray, Joseph C.
    Hsu, Melinda
    Guo, Matthew Z.
    Ettinger, David S.
    Feliciano, Josephine
    Forde, Patrick
    Hann, Christine L.
    Lam, Vincent K.
    Levy, Benjamin
    Anagnostou, Valsamo
    Brahmer, Julie R.
    Marrone, Kristen A.
    CLINICAL LUNG CANCER, 2024, 25 (02) : 109 - 118
  • [9] Immunotherapy in frail non-small-cell lung cancer patients
    Gijtenbeek, Rolof G. P.
    Noordhof, Anneloes L.
    Asmara, Oke D.
    Groen, Harry J. M.
    van Geffen, Wouter H.
    LANCET, 2024, 403 (10440): : 1986 - 1986
  • [10] Immunotherapy rechallenge in patients with non-small-cell lung cancer
    Espana, S.
    Guasch, I.
    Carcereny, E.
    PULMONOLOGY, 2020, 26 (04): : 252 - 254
12345